Description

Simple

Clinical

Overview

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Maxacalcitol
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1alpha-Hydroxyvitamin D5
The risk or severity of adverse effects can be increased when Maxacalcitol is combined with 1alpha-Hydroxyvitamin D5.
1alpha,24S-Dihydroxyvitamin D2
The risk or severity of adverse effects can be increased when 1alpha,24S-Dihydroxyvitamin D2 is combined with Maxacalcitol.
Acetyldigitoxin
The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Maxacalcitol is combined with Acetyldigitoxin.
Acetyldigoxin
The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Maxacalcitol is combined with Acetyldigoxin.
Aldosterone
The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Aldosterone.
Alfacalcidol
The risk or severity of adverse effects can be increased when Alfacalcidol is combined with Maxacalcitol.
Aluminum hydroxide
The serum concentration of Aluminum hydroxide can be increased when it is combined with Maxacalcitol.
Beclomethasone dipropionate
The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Beclomethasone dipropionate.
Becocalcidiol
The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Maxacalcitol.
Bendroflumethiazide
The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Maxacalcitol.
Benzthiazide
The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Maxacalcitol.
Betamethasone
The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Betamethasone.
Betamethasone phosphate
The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Betamethasone phosphate.
Budesonide
The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Budesonide.
Calcifediol
The risk or severity of adverse effects can be increased when Calcifediol is combined with Maxacalcitol.
Calcitriol
The risk or severity of adverse effects can be increased when Calcitriol is combined with Maxacalcitol.
Calcium
The risk or severity of adverse effects can be increased when Calcium is combined with Maxacalcitol.
Calcium acetate
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Maxacalcitol.
Calcium carbonate
The risk or severity of adverse effects can be increased when Calcium carbonate is combined with Maxacalcitol.
Calcium cation
The risk or severity of adverse effects can be increased when Calcium cation is combined with Maxacalcitol.